Opus Genetics, Inc. - Common Stock (IRD)
1.0200
+0.0498 (5.13%)
NASDAQ · Last Trade: Jun 26th, 6:06 PM EDT
Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.
Via Benzinga · June 26, 2025
Via Benzinga · June 20, 2025

Unusual volume stocks are being observed in Tuesday's session.
Via Chartmill · June 3, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · March 21, 2025
Via Benzinga · March 18, 2025